- Home
- PLUG vs MYGN Comparison
PLUG vs MYGN Comparison
Compare PLUG & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLUG
- MYGN
- Stock Information
- Founded
- PLUG 1997
- MYGN 1991
- Country
- PLUG United States
- MYGN United States
- Employees
- PLUG N/A
- MYGN N/A
- Industry
- PLUG Industrial Machinery/Components
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PLUG Energy
- MYGN Health Care
- Exchange
- PLUG Nasdaq
- MYGN Nasdaq
- Market Cap
- PLUG 1.8B
- MYGN 2.0B
- IPO Year
- PLUG 1999
- MYGN 1995
- Fundamental
- Price
- PLUG $2.33
- MYGN $13.50
- Analyst Decision
- PLUG Hold
- MYGN Hold
- Analyst Count
- PLUG 21
- MYGN 11
- Target Price
- PLUG $3.82
- MYGN $24.27
- AVG Volume (30 Days)
- PLUG 59.9M
- MYGN 1.1M
- Earning Date
- PLUG 02-28-2025
- MYGN 02-25-2025
- Dividend Yield
- PLUG N/A
- MYGN N/A
- EPS Growth
- PLUG N/A
- MYGN N/A
- EPS
- PLUG N/A
- MYGN N/A
- Revenue
- PLUG $659,505,000.00
- MYGN $823,600,000.00
- Revenue This Year
- PLUG N/A
- MYGN $13.82
- Revenue Next Year
- PLUG $27.12
- MYGN $4.59
- P/E Ratio
- PLUG N/A
- MYGN N/A
- Revenue Growth
- PLUG N/A
- MYGN 12.15
- 52 Week Low
- PLUG $1.60
- MYGN $12.87
- 52 Week High
- PLUG $5.14
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- PLUG 50.92
- MYGN 32.61
- Support Level
- PLUG $2.12
- MYGN $13.04
- Resistance Level
- PLUG $2.52
- MYGN $13.77
- Average True Range (ATR)
- PLUG 0.21
- MYGN 0.60
- MACD
- PLUG -0.03
- MYGN 0.14
- Stochastic Oscillator
- PLUG 40.38
- MYGN 24.51
About PLUG Plug Power Inc.
Plug Power is building an end-to-end green hydrogen ecosystem-from production, storage, and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets, including material handling, e-mobility, power generation, and industrial applications.
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.